Recent Developments in Selective Agonists and Antagonists Acting at Purine and Pyrimidine Receptors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 66 citations in OpenAlex.

1. The Effects of Adenosine A1/A3 Receptors Agonist on Improving the Outcomes of TBI and Stroke: Focus on AST-004.Current neurology and neuroscience reports · 2026
   Review
2. Exploring human adenosine A3 receptor complementarity and activity for adenosine analogues modified in the ribose and purine moiety.Bioorganic & medicinal chemistry · 2005
   Article
3. Purine and pyrimidine (P2) receptors as drug targets.Journal of medicinal chemistry · 2002
   Review
4. Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist.Journal of medicinal chemistry · 2002
   Article
5. Interactions of flavones and other phytochemicals with adenosine receptors.Advances in experimental medicine and biology · 2002
   Review
6. Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies.Journal of medicinal chemistry · 2001
   Article
7. Activation of the A3 adenosine receptor affects cell cycle progression and cell growth.Naunyn-Schmiedeberg's archives of pharmacology · 2000
   Article
8. Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.Journal of medicinal chemistry · 1998
   Article
9. Activation of the A2A adenosine receptor inhibits nitric oxide production in glial cells.FEBS letters · 1998
   Article
10. Adenosine A3 receptors: novel ligands and paradoxical effects.Trends in pharmacological sciences · 1998
    Review
11. Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model.Journal of medicinal chemistry · 1998
    Article
12. Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.Journal of medicinal chemistry · 1997
    Article
13. Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists.Biochemical and biophysical research communications · 1997
    Article
14. ADrug development research
    Article
15. Functionalized congeners of 1,4-dihydropyridines as antagonist molecular probes for A3 adenosine receptors.Bioconjugate chemistry
    Article
16. Adenosine ADrug development research
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

Abstract

Indexed as